Table 3.
Adjusted risks of end-stage kidney disease, macrovascular events, cardiovascular death, and all-cause death by baseline albuminuria levela
| End Point | Normoalbuminuria (n = 7877) | Micro- or Macroalbuminuria (n = 3263) | HR (95% CI) |
|---|---|---|---|
| End-stage kidney diseaseb | 19 (0.2%) | 27 (0.8%) | 1.99 (1.08 to 3.70) |
| Macrovascular eventsc | 585 (7.4%) | 415 (12.7%) | 1.61 (1.42 to 1.84) |
| Cardiovascular death | 239 (3.0%) | 229 (7.0%) | 2.07 (1.72 to 2.50) |
| All-cause death | 496 (6.3%) | 383 (11.7%) | 1.70 (1.48 to 1.96) |
a
Adjusted for age, gender, HbA1c, SBP, DBP, LDL cholesterol, HDL cholesterol, triglycerides, BMI, eGFR, current smoking, and current alcohol use.
b
Defined as requirement of renal replacement therapy or renal death.
c
Composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.